Expert Profile

Share QR code Edit Profile

Charles Heine

MD-INST FOR THERAPEUTIC INNOV | COLLEGE-MEDICINE

View:

Select
All (all in one) Research Terms and Keywords Publications Co-Investigator Network Websites Contact

All
Research
Publications
Network
Websites
Contact

Research Terms & Keywords

Research Terms

Medical Sciences

Industries

Health Care

Research Projects

Ends

Title

07-2023

Merck Study Agreement Merck Study Agreement

09-2022

Evaluation of antimicrobial peptides for Biodefense Evaluation of antimicrobial peptides for Biodefense

08-2022

In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens

06-2022

Evaluation of Lefamulin dose to survival in mice following aerosol exposure to F. tularensis SchuS4 Evaluation of Lefamulin dose to survival in mice following aerosol exposure to F. tularensis SchuS4

03-2022

In Vitro Microbiological Evaluations of Medinamycin (MedM), MsbA inhibitor P2129, MedM + SPR741, and MsbA inhibitor P2129 + SPR741 Against Category A and B Bacterial Pathogen Panels In Vitro Microbiological Evaluations of Medinamycin (MedM), MsbA inhibitor P2129, MedM + SPR741, and MsbA inhibitor P2129 + SPR741 Against Category A and B Bacterial Pathogen Panels

12-2021

Project Bioshield Project Bioshield

07-2021

Battelle Subcontract 778380 SAB Year 1 Battelle Subcontract 778380 SAB Year 1

06-2021

Evaluation of air purification methods for SARS-CoV-2 Evaluation of air purification methods for SARS-CoV-2

05-2021

Teixobactin Development for Anthrax Teixobactin Development for Anthrax

11-2020

MICs for Wockhardt WCK-5222 MICs for Wockhardt WCK-5222

10-2020

In vitro testing of the 40 isolate panel of B. pseudomallei isolates In vitro testing of the 40 isolate panel of B. pseudomallei isolates

07-2020

KBP Biosciences Research Agreement - In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens KBP Biosciences Research Agreement - In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens

08-2019

EPDG-15-GC072-S-0001 Task 4.7 Dose Loading Efficacy Study EPDG-15-GC072-S-0001 Task 4.7 Dose Loading Efficacy Study

08-2019

EPDG-15-GC072-S-0001 Task 4.7 PK Study EPDG-15-GC072-S-0001 Task 4.7 PK Study

04-2019

In Vitro Microbiological Evaluation of Polymyxin Analogs versus Category A and B Pathogens In Vitro Microbiological Evaluation of Polymyxin Analogs versus Category A and B Pathogens

03-2019

Confirmatory Efficacy Study in Bp Infected Mice Confirmatory Efficacy Study in Bp Infected Mice

10-2018

Evaluation of the improved GC-072 formulation plasma and lung ELF PK in uninfected and the Bp infected mice model Evaluation of the improved GC-072 formulation plasma and lung ELF PK in uninfected and the Bp infected mice model

09-2018

Pharmacokinetic analysis of nonhuman primate data for US Army######### Pharmacokinetic analysis of nonhuman primate data for US Army#########

06-2018

Evaluation of single and twice daily dosing of EBX-205 on survival of mice following aerosol exposure to B.pseudomallei 1026b Evaluation of single and twice daily dosing of EBX-205 on survival of mice following aerosol exposure to B.pseudomallei 1026b

02-2018

MIC90 determination of 2 ?-lactam inhancer antibacterial compounds from Wockhardt against sets of 30 strains each of Yersinia pestis, Francisella tularensis, Burkholderia mallei(12 strains) and Burkholderia pseudomallei. MIC90 determination of 2 ?-lactam inhancer antibacterial compounds from Wockhardt against sets of 30 strains each of Yersinia pestis, Francisella tularensis, Burkholderia mallei(12 strains) and Burkholderia pseudomallei.

01-2018

Evaluation of EBX-205 against of B. Pseudomallei in virto Evaluation of EBX-205 against of B. Pseudomallei in virto

01-2018

Exhibit N - MIC testing of BSC 3 extended MIC Panel in connection with Achaogen#s C-Scape project as outlined in University of Florida proposal #ITI Antibiotic Susceptibility Determinations# Exhibit N - MIC testing of BSC 3 extended MIC Panel in connection with Achaogen#s C-Scape project as outlined in University of Florida proposal #ITI Antibiotic Susceptibility Determinations#

01-2018

ITI Antibiotic Susceptibility Determinations ITI Antibiotic Susceptibility Determinations

01-2018

ANTIBIOTIC SUSCEPTIBILITY AND SPONTANEOUS RESISTANCE DEVELOPMENT FOR VARIOUS ISOLATES OF B. PSEUDOMALLEI ANTIBIOTIC SUSCEPTIBILITY AND SPONTANEOUS RESISTANCE DEVELOPMENT FOR VARIOUS ISOLATES OF B. PSEUDOMALLEI

12-2017

Evaluation of EBX-205 dose to survival in mice following aerosol exposure to B. pseudomallei 1026b Evaluation of EBX-205 dose to survival in mice following aerosol exposure to B. pseudomallei 1026b

12-2017

HDTRA114-CBM-06-1-0052 titled GC-072: The First Oral Antibiotic for the Treatment of Acute Melioidosis and Select Agents HDTRA114-CBM-06-1-0052 titled GC-072: The First Oral Antibiotic for the Treatment of Acute Melioidosis and Select Agents

08-2017

Salary for protocol development and ACURO review Salary for protocol development and ACURO review

07-2017

In Vitro Antibiotic Therapeutic Services in Support of protocol #AP-10-047G: Pharmokinetic and pharacodynamic analyses of intravenous Moxifloxican in Non-Human Primates using appropriate computer programs. In Vitro Antibiotic Therapeutic Services in Support of protocol #AP-10-047G: Pharmokinetic and pharacodynamic analyses of intravenous Moxifloxican in Non-Human Primates using appropriate computer programs.

05-2017

WITI Antibiotic Susceptibility Determinations WITI Antibiotic Susceptibility Determinations

12-2016

Task 2.5 In Vivo Efficacy Study to Identify Most Effective Doses Task 2.5 In Vivo Efficacy Study to Identify Most Effective Doses

04-2016

EVALUATION OF THE POTENTIAL OF GSK2140944 IN THE VIVO MURINEINHALATIONAL MODELS FOR YERSINIA PESTIS: Study #1 EVALUATION OF THE POTENTIAL OF GSK2140944 IN THE VIVO MURINEINHALATIONAL MODELS FOR YERSINIA PESTIS: Study #1

12-2015

Tetraphase MSA TP-271 Tetraphase MSA TP-271

11-2015

GSK BARDA Evaluation of GSK2251052 GSK BARDA Evaluation of GSK2251052

11-2015

Battelle Rempex/BARDA - TOA Battelle Rempex/BARDA - TOA

10-2015

Evaluation of synergistic activity and efficacy of combi Evaluation of synergistic activity and efficacy of combi

05-2015

CEMPRA: MIC/MBCs and Time-Kill kinetics CEMPRA: MIC/MBCs and Time-Kill kinetics

01-2015

MIC determination of 15 antibacterial compounds MIC determination of 15 antibacterial compounds

01-2015

Wockhardt Antibiotic Susceptibilities- Initial Screen Wockhardt Antibiotic Susceptibilities- Initial Screen

12-2012

Trius NIH NIAID SOW 2 Trius NIH NIAID SOW 2

12-2012

Trius NIH NIAID SOW3 Trius NIH NIAID SOW3

09-2012

SOW D Task 1: Achaogen BARDA ACHN-490 Development SOW D Task 1: Achaogen BARDA ACHN-490 Development

09-2012

SOW F Task 3: Achaogen BARDA ACHN-490 Development SOW F Task 3: Achaogen BARDA ACHN-490 Development

09-2012

SOW G Task 4: Achaogen BARDA ACHN-490 Development SOW G Task 4: Achaogen BARDA ACHN-490 Development

Publications

Search Google Scholar for Charles Heine